Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02213042
Title Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | ESP | AUT

Facility Status City State Zip Country Details
Novartis Investigative Site Mobile Alabama 36608 United States Details
Novartis Investigative Site Boston Massachusetts 02114 United States Details
Novartis Investigative Site Houston Texas 77030 United States Details
Novartis Investigative Site Berazategui Buenos Aires B1880BBF Argentina Details
Novartis Investigative Site Ciudad Autonoma de Buenos Aires Buenos Aires C1125ABD Argentina Details
Novartis Investigative Site Viedma Río Negro R8500ACE Argentina Details
Novartis Investigative Site Rosario Santa Fe S2000KZE Argentina Details
Novartis Investigative Site Ciudad Autonoma de Buenos Aires C1025ABI Argentina Details
Novartis Investigative Site Cordoba X5004FHP Argentina Details
Novartis Investigative Site La Rioja F5300COE Argentina Details
Novartis Investigative Site San Miguel de Tucuman T4000IAK Argentina Details
Novartis Investigative Site Salzburg A-5020 Austria Details
Novartis Investigative Site Wien 1090 Austria Details
Novartis Investigative Site Salvador Bahía 41825-010 Brazil Details
Novartis Investigative Site Belo Horizonte Minas Gerais 30130-090 Brazil Details
Novartis Investigative Site Porto Alegre Rio Grande Do Sul 90430-090 Brazil Details
Novartis Investigative Site Porto Alegre Rio Grande Do Sul 90470-340 Brazil Details
Novartis Investigative Site Porto Alegre Rio Grande Do Sul 90610-000 Brazil Details
Novartis Investigative Site Itajai Santa Catarina 88301220 Brazil Details
Novartis Investigative Site Barretos São Paulo 14784-400 Brazil Details
Novartis Investigative Site Sao Paulo São Paulo 01236030 Brazil Details
Novartis Investigative Site Sao Paulo São Paulo 01317-001 Brazil Details
Novartis Investigative Site Sao Jose do Rio Preto 15090-000 Brazil Details
Novartis Investigative Site Pok Fu Lam Hong Kong Details
Novartis Investigative Site Pokfulam Hong Kong Details
Novartis Investigative Site Milano Lombardia 20133 Italy Details
Novartis Investigative Site Milano Lombardia 20141 Italy Details
Novartis Investigative Site Mexico 06760 Mexico Details
Novartis Investigative Site Arequipa Peru Details
Novartis Investigative Site Lima Lima 34 Peru Details
Novartis Investigative Site Cebu 6000 Philippines Details
Novartis Investigative Site Manila 1000 Philippines Details
Novartis Investigative Site Kazan 420029 Russian Federation Details
Novartis Investigative Site Moscow 115 478 Russian Federation Details
Novartis Investigative Site Ryazan 390011 Russian Federation Details
Novartis Investigative Site St. Petersburg 197022 Russian Federation Details
Novartis Investigative Site St. Petersburg 197758 Russian Federation Details
Novartis Investigative Site Volzhskiy 404130 Russian Federation Details
Novartis Investigative Site Barcelona 08035 Spain Details
Novartis Investigative Site Barcelona 08036 Spain Details
Novartis Investigative Site Donostia 20014 Spain Details
Novartis Investigative Site Madrid 28034 Spain Details
Novartis Investigative Site Madrid 28040 Spain Details
Novartis Investigative Site Madrid 28041 Spain Details
Novartis Investigative Site Malaga 29010 Spain Details
Novartis Investigative Site Sevilla 41013 Spain Details
Novartis Investigative Site Valencia 46010 Spain Details
Novartis Investigative Site Valencia 46015 Spain Details
Novartis Investigative Site Bangkok 10330 Thailand Details
Novartis Investigative Site Chiangmai 50200 Thailand Details
Novartis Investigative Site Phitsanulok 65000 Thailand Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field